EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shared details on Tuesday about its pivotal Phase 3 program of Duravyu (vorolanib intravitreal insert) for diabetic macular edema (DME) and began first patient dosing, anticipated in the first quarter of 2026.DME is the leading cause of vision loss in type 1 and type 2 diabetes patients. Damaged blood vessels leak fluid into the macula, the central portion of the retina responsible for sharp vision needed for routine tasks such as driving or reading.Phase 3 Clini ...